A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

We report the results of a Phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed/refractory acute leukemias using an intermittent dosing regimen. Fifteen patients with advanced leukemia (Acute myeloid leukemia(AML), 2=Acute lymphoblastic leukemia(ALL), 1 Biphenotypic) and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Pratz, Keith W., Cho, Eunpi, Levis, Mark J., Karp, Judith E., Gore, Steven D., McDevitt, Michael, Stine, Adam, Zhao, Ming, Baker, Sharyn D., Carducci, Michael A., Wright, John J., Rudek, Michelle A., Smith, B. Douglas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2921005/
https://ncbi.nlm.nih.gov/pubmed/20535150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.132
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak